AI interventions in cancer screening: balancing equity and cost-effectiveness
Clinical Snapshot
PICO Framework
| P — Population | Individuals eligible for cancer screening programmes, with particular focus on non-attenders and underserved populations; breast cancer screening used as primary case study |
| I — Intervention | Artificial intelligence-assisted cancer screening interventions (e.g., AI-aided image reading, triage, workflow optimisation) with explicit equity-oriented design and cost-saving reinvestment strategies |
| C — Comparator | Conventional cancer screening programmes without AI integration; AI interventions that benefit only existing attenders without addressing non-attender engagement |
| O — Outcomes | Health equity in cancer screening participation and outcomes; cost-effectiveness and cost-saving potential of AI interventions; resource reallocation to non-attenders; reduction in disparities in cancer outcomes; transparency in policy decision-making |
Bottom Line
Roadevin and Hill present a timely and well-reasoned ethical argument that AI integration into cancer screening programmes risks entrenching existing health disparities if designed solely to optimise performance among current attenders. Using breast cancer screening as a case study, they argue that AI must be evaluated not only on diagnostic accuracy and cost-effectiveness but on its capacity to reduce inequities — particularly for non-attenders who bear the greatest burden of late-stage cancer diagnosis. The paper's core contribution is its advocacy for equity-weighted health economic methods, specifically distributional cost-effectiveness analysis, to make the opportunity costs of AI investment explicit and to identify cost-saving interventions whose savings can be reinvested in non-attender engagement. While the paper presents no original data and stops short of providing a worked quantitative example, its normative framework is methodologically sound and policy-relevant. For Australian clinicians and health system planners, the arguments map directly onto documented participation disparities in BreastScreen Australia and the evolving MSAC and TGA landscape for AI-based medical devices. Senior clinicians and programme directors should advocate for equity impact assessments as a standard component of AI procurement and health technology assessment in screening contexts.
Key Findings
P Value: Not applicable — no statistical testing performed
Effect Size: No empirical effect size reported. The paper references the established evidence base that non-attenders experience disproportionately worse cancer outcomes, but does not quantify this within the paper.
Primary Outcome: Normative conclusion that AI interventions in cancer screening must be designed to address health inequities by prioritising non-attenders, not merely optimising outcomes for existing attenders. The paper argues that cost-saving AI interventions should enable reinvestment into non-attender engagement strategies.
Nnt Or Sensitivity: Not applicable. The paper recommends distributional cost-effectiveness analysis and decision modelling as methods to generate such estimates in future work, but does not produce them.
Confidence Interval: Not applicable — no quantitative analysis performed
Clinical Application
The methodological recommendations (distributional cost-effectiveness analysis, decision modelling for equity) are technically feasible but require specialist health economics expertise and access to disaggregated screening participation and outcomes data. Implementation of equity-oriented AI procurement criteria would require regulatory and commissioning framework changes. Practical barriers include data infrastructure, AI vendor transparency obligations, and workforce capacity for non-attender outreach. Highly relevant to Australian practice. BreastScreen Australia operates as a free, organised population-based programme with documented disparities in participation among Aboriginal and Torres Strait Islander women, women from culturally and linguistically diverse backgrounds, women in rural and remote areas, and women with disabilities. The Medical Services Advisory Committee (MSAC) evaluates new technologies including AI-assisted screening, and the paper's advocacy for distributional cost-effectiveness analysis aligns with MSAC's increasing attention to equity in health technology assessment. The TGA regulates AI-based medical devices as Software as a Medical Device (SaMD), but regulatory frameworks for equity performance requirements remain underdeveloped. RACGP guidelines on preventive care and cancer screening could incorporate equity-weighted referral and recall strategies consistent with the paper's recommendations. The paper's framework is directly applicable to Australian health system planning, particularly given the National Cancer Screening Register infrastructure. Policymakers, health technology assessment bodies, and clinical programme directors responsible for organised cancer screening programmes in high-income countries. Clinically relevant to radiologists, oncologists, public health physicians, and primary care practitioners involved in screening pathway design and patient engagement.
Abstract
This paper examines the integration of artificial intelligence (AI) into cancer screening programmes, focusing on the associated equity challenges and resource allocation implications. While AI technologies promise significant benefits-such as improved diagnostic accuracy, shorter waiting times, reduced reliance on radiographers, and overall productivity gains and cost-effectiveness-current interventions disproportionately favour those already engaged in screening. This neglect of non-attenders, who face the worst cancer outcomes, exacerbates existing health disparities and undermines the core objectives of screening programmes.Using breast cancer screening as a case study, we argue that AI interventions must not only improve health outcomes and demonstrate cost-effectiveness but also address inequities by prioritising non-attenders. To this end, we advocate for the design and implementation of cost-saving AI interventions. Such interventions could enable reinvestment into strategies specifically aimed at increasing engagement among non-attenders, thereby reducing disparities in cancer outcomes. Decision modelling is presented as a practical method to identify and evaluate these cost-saving interventions. Furthermore, the paper calls for greater transparency in decision-making, urging policymakers to explicitly account for the equity implications and opportunity costs associated with AI investments. Only then will they be able to balance the promise of technological innovation with the ethical imperative to improve health outcomes for all, particularly underserved populations. Methods such as distributional cost-effectiveness analysis are recommended to quantify and address disparities, ensuring more equitable healthcare delivery.
References
- 1.Roadevin, C., & Hill, H. (2026). AI interventions in cancer screening: balancing equity and cost-effectiveness. Journal of Medical Ethics. Advance online publication. https://doi.org/10.1136/jme-2025-110707
Related Research
The American journal of pathology
An Integrated Machine Learning and Genomic Framework for Precise Detection of Gastric Cancer
3 Aug 2026
Current opinion in chemical biology
Prediction of protein-protein interactions and co-complex models with deep learning
3 Aug 2026
European journal of radiology
A CT-based deep learning model to differentiate between benign and malignant adrenal lesions
3 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service